Compare SYSCO Corporation (SYY) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SYSCO Corporation vs Viatris Inc — how do they compare? SYSCO Corporation trades at $81.58 (market cap $38.25B), while Viatris Inc trades at $16.45 (market cap $19.09B). The key difference: SYSCO Corporation is far larger — about 2× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.89%). Which is the better fit depends on your goals.
| SYY | VTRS | |
|---|---|---|
Market Cap | $38.25B | $19.09B |
Sector | Consumer Staples | Health |
52-Week High | $91.16 | $17.86 |
52-Week Low | $69.30 | $9.49 |
Enterprise Value | $51.43B | $31.21B |
Dividend Yield | 2.76% | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sysco Corporation (SYY) trades at $79.84, down 0.26% with mixed technical signals showing bullish oscillators but bearish moving averages. The company reported solid Q2 2026 earnings beat ($1.53 vs $1.51 expected) and maintains strong revenue growth, reaching $81.37B in 2025. Recent news highlights the company's $500M AI efficiency program and reaffirmed fiscal 2027 guidance, while analysts maintain a 60% buy rating with $88.25 consensus target.
Sysco presents a compelling investment case with attractive valuation (P/S 0.45), strong institutional interest, and AI-driven efficiency initiatives. However, risks include integration challenges from the Jetro Restaurant Depot acquisition, rising debt levels, and margin pressure from inflationary costs. The stock offers 10% upside to analyst targets but requires monitoring of execution on growth initiatives.
Viatris (VTRS) trades at $16.61, down 1.6% over the past 24 hours. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported a net loss of $3.51 billion in 2025 despite revenue of $14.30 billion, though recent quarters have shown earnings beats. Positive cash flow generation and a dividend payment highlight financial stability, while analyst sentiment is mixed with a majority hold rating.
The outlook for VTRS hinges on its ability to return to profitability and sustain operational improvements. Investment opportunities include strong cash flow, deleveraging progress, and pipeline developments, but risks involve persistent net losses, competitive pressures, and potential regulatory impacts from proposed generic drug tariffs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
